Full Press Release Details
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
SYDNEY, AUSTRALIA 23 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a 1,804,341 (~
A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Cr dit d Imp t Recherche scheme (CIR).
The Cr dit d Imp t Recherche (CIR), meaning Research Tax Credit , is a French government tax incentive by which
French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
Immutep qualifies to
receive the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted
in the European Union in the 2021 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in
The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of
Immutep is a globally active
biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and
expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble
LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products,
including antibodies for immune response modulation, are being developed by Immutep s large pharmaceutical partners.
Level 33, Australia Square
264 George Street, Sydney NSW 2000
This announcement has been authorised for release by the Chief Executive Officer, Marc Voigt.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
Level 33, Australia Square
264 George Street, Sydney NSW 2000